[Correlation between postoperative neutrophil to lymphocyte ratio and recurrence and prognosis of hepatocellular carcinoma after radical liver resection]
- PMID: 29860764
- DOI: 10.3760/cma.j.issn.0253-3766.2018.05.009
[Correlation between postoperative neutrophil to lymphocyte ratio and recurrence and prognosis of hepatocellular carcinoma after radical liver resection]
Abstract
Objective: To investigate the correlation between postoperative peripheral blood neutrophil to lymphocyte ratio (NLR) and recurrence and prognosis of patients with hepatocellular carcinoma (HCC). Methods: The clinicopathological and follow-up data of 344 patients with HCC who underwent radical liver resection from May 2010 to April 2014 were analyzed retrospectively. Results: Of the 344 patients, 104 had early recurrence and 84 had late recurrence. Receiver operating characteristic (ROC) curve analysis showed that the NLR predicted area under the curve (AUC) of early recurrence was 0.622 (P<0.001), the optimal cut-off value was 2.41. The AUC of late recurrence was 0.634 (P=0.001), the optimal cut-off value was 2.15. Cox multivariate analysis showed the serum concentration of hepatitis B surface antigen (HR=2.508, 95% CI: 1.311-4.798), microvascular invasion (HR=2.422, 95% CI: 1.239-4.734), Milan criteria (HR=2.373, 95% CI: 1.427-3.948) and postoperative NLR (HR=2.285, 95% CI: 1.379-3.788) were independent risk factors of early recurrence after HCC resection. Postoperative NLR (HR=2.927, 95% CI: 1.630-5.255), liver cirrhosis (HR=2.531, 95% CI: 1.291-4.962) and serum concentration of albumin (HR=2.257, 95% CI: 1.251-4.073) were independent risk factors of late recurrence after HCC resection. The median recurrence-free survival (RFS) of the 344 patients was 45.0 months, and the median overall survival (OS) was 63.2 months. ROC curve analysis showed that the postoperative NLR predicted 5-year survival AUC was 0.689 (P<0.05), with an optimal cutoff of 2.29. Cox multivariate analysis showed microvascular invasion (HR=2.247, 95% CI: 1.534-3.291), postoperative NLR (HR=2.217, 95% CI: 1.653-2.974), and liver cirrhosis (HR=1.685, 95% CI: 1.168-2.431), Milan criteria (HR=1.679, 95% CI: 1.238-2.277), serum concentration of hepatitis B surface antigen (HR=1.623, 95% CI: 1.102-2.392), serum concentration of albumin (HR=1.43, 95% CI: 1.066-1.918) were independent factors of RFS after HCC resection, while microvascular invasion (HR=3.862, 95% CI: 2.407-6.197), Barcelona staging (HR=2.864, 95% CI: 1.600-5.125), postoperative NLR (HR=2.688, 95% CI: 1.782-4.055), liver cirrhosis (HR=2.039, 95% CI: 1.184-3.514), serum concentration of albumin (HR=1.81, 95% CI: 1.204-2.720) were independent factors of OS. Conclusions: For HCC patients who receive radical liver resection, postoperative NLR ≥2.29 implicates poor prognosis. Moreover, postoperative NLR ≥2.41 suggests early recurrence, while NLR ≥2.15 suggests late recurrence.
目的:探讨肝癌手术后中性粒细胞和淋巴细胞比值(NLR)与肝癌患者复发、生存的关系。 方法:收集2010年5月至2014年4月间行根治性切除的344例原发性肝细胞癌(HCC)患者的临床病理资料和随访资料。绘制术后NLR预测复发和生存的受试者工作特征(ROC)曲线并确定最佳界值,采用单因素和多因素分析评价复发和生存的影响因素。 结果: 344例患者中,早期复发104例,晚期复发84例。ROC曲线分析显示,术后NLR预测早期复发的曲线下面积(AUC)为0.622(P<0.001),最佳界值为2.41;预测晚期复发的AUC为0.634(P=0.001);最佳界值为2.15。Cox多因素分析显示,乙肝表面抗原(HR=2.508,95%CI:1.311~4.798)、微血管侵犯(HR=2.422,95%CI:1.239~4.734)、米兰标准(HR=2.373,95%CI:1.427~3.948)、术后NLR(HR=2.285,95%CI:1.379~3.788)是HCC切除术后早期复发的独立影响因素,术后NLR(HR=2.927,95%CI:1.630~5.255)、肝硬化(HR=2.531,95%CI:1.291~4.962)、白蛋白(HR=2.257,95%CI:1.251~4.073)是HCC切除术后晚期复发的独立影响因素。344例患者的中位无复发生存时间(RFS)为45.0个月,中位总生存时间(OS)为63.2个月。ROC曲线分析显示,术后NLR预测患者5年生存的AUC为0.689(P<0.05),最佳界值为2.29。Cox多因素分析显示,微血管侵犯(HR=2.247,95%CI:1.534~3.291)、术后NLR(HR=2.217, 95% CI:1.653~2.974)、肝硬化(HR=1.685,95%CI:1.168~2.431)、米兰标准(HR=1.679,95%CI:1.238~2.277)、乙肝表面抗原(HR=1.623,95%CI:1.102~2.392)、白蛋白(HR=1.43,95%CI:1.066~1.918)为HCC切除术后RFS的独立影响因素,微血管侵犯(HR=3.862,95%CI:2.407~6.197)、巴塞罗那分期(HR=2.864,95%CI:1.600~5.125)、术后NLR(HR=2.688,95%CI:1.782~4.055)、肝硬化(HR=2.039,95%CI:1.184~3.514)、白蛋白(HR=1.81,95%CI:1.204~2.720)为OS的独立影响因素。 结论:对于根治性手术切除的HCC患者,术后NLR≥2.29提示预后不良,≥2.41提示具有早期复发风险,≥2.15提示具有晚期复发风险。.
Keywords: Carcinoma, hepatocellular; Neutrophil to lymphocyte ratio; Prognosis; Recurrence.
Similar articles
-
Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival.J Surg Res. 2014 Dec;192(2):402-8. doi: 10.1016/j.jss.2014.05.078. Epub 2014 Jun 2. J Surg Res. 2014. PMID: 24998425
-
Blood Neutrophil-to-Lymphocyte Ratio Predicts Tumor Recurrence in Patients with Hepatocellular Carcinoma within Milan Criteria after Hepatectomy.Yonsei Med J. 2016 Sep;57(5):1115-23. doi: 10.3349/ymj.2016.57.5.1115. Yonsei Med J. 2016. PMID: 27401641 Free PMC article.
-
Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.Oncotarget. 2016 Nov 1;7(44):72276-72289. doi: 10.18632/oncotarget.10848. Oncotarget. 2016. PMID: 27472390 Free PMC article.
-
The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis.Int J Surg. 2018 Jul;55:73-80. doi: 10.1016/j.ijsu.2018.05.022. Epub 2018 May 19. Int J Surg. 2018. PMID: 29787804 Review.
-
Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.Cell Physiol Biochem. 2017;44(3):967-981. doi: 10.1159/000485396. Epub 2017 Nov 27. Cell Physiol Biochem. 2017. PMID: 29179180 Review.
Cited by
-
Neutrophils as potential therapeutic targets in hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2022 Apr;19(4):257-273. doi: 10.1038/s41575-021-00568-5. Epub 2022 Jan 12. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35022608 Review.
-
Clinical value of prophylactic transcatheter arterial chemoembolization treatment in patients with hepatocellular carcinoma.Am J Transl Res. 2022 May 15;14(5):3225-3232. eCollection 2022. Am J Transl Res. 2022. PMID: 35702096 Free PMC article.
-
Significant association between high neutrophil-lymphocyte ratio and poor prognosis in patients with hepatocellular carcinoma: a systematic review and meta-analysis.Front Immunol. 2023 Sep 21;14:1211399. doi: 10.3389/fimmu.2023.1211399. eCollection 2023. Front Immunol. 2023. PMID: 37809083 Free PMC article.
-
Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.Cancer Med. 2024 Feb;13(4):e7018. doi: 10.1002/cam4.7018. Cancer Med. 2024. PMID: 38457189 Free PMC article. Review.
-
Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.World J Gastroenterol. 2020 Sep 7;26(33):5022-5049. doi: 10.3748/wjg.v26.i33.5022. World J Gastroenterol. 2020. PMID: 32952347 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous